X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 09/03/24
X4 Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 08/08/24
X4 Pharmaceuticals: Catch The Falling Knife After Propitious Mavorixafor DataSeeking Alpha • 07/02/24
X4 Pharmaceuticals Announces Positive Interim Clinical Data from Ongoing Six-Month Phase 2 Trial of Mavorixafor in Chronic Neutropenia (CN) and Initiation of Pivotal Phase 3 CN TrialGlobeNewsWire • 06/27/24
X4 Pharmaceuticals to Host Virtual Investor Event on June 27, 2024 to Review New Mavorixafor Clinical Data from Ongoing Phase 2 Trial in Chronic NeutropeniaGlobeNewsWire • 05/29/24
X4 Pharmaceuticals to Participate in the H.C. Wainwright 2nd Annual BioConnect Investor ConferenceGlobeNewsWire • 05/13/24
X4 Pharmaceuticals Announces $125 Million Capital Infusion from $105 Million Sale of Priority Review Voucher and $20 Million Drawdown from Existing Loan FacilityGlobeNewsWire • 05/09/24
X4 Pharmaceuticals Reports First-Quarter 2024 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 05/07/24
X4 Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)GlobeNewsWire • 05/01/24
X4 Pharmaceuticals to Report First-Quarter 2024 Financial Results and Host a Conference Call and Webcast on May 7, 2024GlobeNewsWire • 04/30/24
X4 Pharmaceuticals Announces FDA Approval of XOLREMDI™ (mavorixafor) Capsules, First Drug Indicated in Patients with WHIM SyndromeGlobeNewsWire • 04/29/24
X4 Pharmaceuticals Reports Fourth-Quarter and Full-Year 2023 Financial Results and Provides Corporate UpdateGlobeNewsWire • 03/21/24
X4 Pharmaceuticals to Report Fourth-Quarter and Full Year 2023 Financial Results and Host a Conference Call and Webcast on March 21, 2024GlobeNewsWire • 03/12/24
X4: Dip Following Mixed Results In Chronic Neutropenia Indication Worth BuyingSeeking Alpha • 12/14/23
X4 Pharmaceuticals Announces Presentation of Additional Data from Mavorixafor Phase 2 Trial in Chronic Neutropenia at ASH 2023GlobeNewsWire • 12/09/23
X4 Pharmaceuticals Reports Third-Quarter 2023 Financial Results and Provides Corporate UpdatesGlobeNewsWire • 11/09/23